{"id":61640,"date":"2024-11-13T12:06:14","date_gmt":"2024-11-13T12:06:14","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/11\/13\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/"},"modified":"2024-11-13T12:06:14","modified_gmt":"2024-11-13T12:06:14","slug":"regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/","title":{"rendered":"Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH"},"content":{"rendered":"<div>\n<p><strong>Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria<\/strong><\/p>\n<p><strong>Initial results for odronextamab in first-line follicular lymphoma showcase compelling monotherapy potential and progress in the confirmatory trial<\/strong><\/p>\n<p><strong>Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma progressing after CAR-T therapy and first results in relapsed\/refractory marginal zone lymphoma <\/strong><\/p>\n<p>TARRYTOWN, N.Y., Nov.  13, 2024  (GLOBE NEWSWIRE) &#8212; Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology (ASH) 2024 Annual Meeting, taking place from December 7-10 in San Diego, CA. The latest research advances demonstrate the potential of Regeneron\u2019s diverse pipeline, which aims to address unmet needs in ten types of blood cancers and disorders. These innovative and differentiated approaches include CD3 bispecific antibodies, costimulatory bispecific antibodies, and a pioneering combination of a monoclonal antibody and small interfering RNA (siRNA).<\/p>\n<p>\u201cOur presentations at ASH demonstrate the progress we are making toward transforming care for a range of blood cancers and disorders where advancements are desperately needed,\u201d said L.\u00a0Andres Sirulnik, M.D., Ph.D., Senior Vice President and Hematology Clinical Development Unit Head at Regeneron. \u201cThese include new head-to-head data exploring a novel combination that aims to maximize disease control in paroxysmal nocturnal hemoglobinuria compared to a standard-of-care treatment, as well as initial results from our confirmatory odronextamab trial in first-line follicular lymphoma. Together, our presentations underscore our commitment to work towards translating scientific breakthroughs to differentiated medicines for hematology patients.\u201d<\/p>\n<p>At ASH, abstracts in blood disorders include an oral presentation from an exploratory cohort of a Phase 3 trial investigating a novel combination of pozelimab with cemdisiran compared to ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were na\u00efve to complement inhibition at baseline. Notably, the presentation will detail interim results from patients who were initially randomized to ravulizumab but crossed over to the combination in an open label extension portion of the trial.<\/p>\n<p>Progress on the odronextamab development program will be featured in twelve abstracts. Among them are initial results in patients with previously untreated follicular lymphoma (FL) from Part 1 of the Phase 3 OLYMPIA-1 confirmatory trial, which consists of a non-randomized safety run-in (Part 1) followed by a randomized efficacy portion (Part 2) comparing odronextamab monotherapy to rituximab plus standard-of-care chemotherapies. Two oral presentations on the ELM-1 and pivotal ELM-2 trials will feature new analyses in settings with significant unmet needs: one in patients with diffuse large B-cell lymphoma (DLBCL) who progressed after CAR-T therapy and the other in relapsed\/refractory (R\/R) marginal zone lymphoma (MZL).<\/p>\n<p>Other notable abstracts include the latest linvoseltamab efficacy and safety results from the pivotal LINKER-MM1 study in R\/R multiple myeloma (MM), preclinical data evaluating a CD38xCD28 costimulatory bispecific antibody in combination with linvoseltamab, and preclinical data on TMPRSS6 inhibition in beta-thalassemia.<\/p>\n<p>The full list of Regeneron presentations at ASH includes:\u00a0<\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"max-width:45%; width:45%; min-width:45%;;border-top: solid black 1pt ; border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \"><strong>Abstract Title<\/strong><\/td>\n<td style=\"max-width:15%; width:15%; min-width:15%;;border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \"><strong>Abstract<\/strong><\/td>\n<td style=\"max-width:15%; width:15%; min-width:15%;;border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \"><strong>Presenter<\/strong><\/td>\n<td style=\"max-width:25%; width:25%; min-width:25%;;border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \"><strong>Session Date\/Time (PT)<\/strong><\/td>\n<\/tr>\n<tr>\n<td colspan=\"4\" style=\"border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><strong>Odronextamab\u00a0<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Abstract #866<br \/>Oral Presentation<br \/>Session<\/p>\n<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Matthew Matasar<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Monday, December 9,\u00a0at 2:45-4:15 pm<\/p>\n<p>Marriott Marquis San Diego Marina,\u00a0Pacific Ballroom Salons 15-17<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Efficacy and Safety of Odronextamab in Relapsed\/Refractory Marginal Zone Lymphoma (R\/R MZL): Data from the R\/R MZL Cohort in the ELM-2 Study<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #862<br \/>Oral Presentation<br \/>Session<\/p>\n<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Tae Min Kim<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Monday, December 9,\u00a0at 2:45-4:15 pm<\/p>\n<p>Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 OLYMPIA-1 Study<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #4411<br \/>Poster\u00a0Presentation<br \/>Session<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Elizabeth Brem<\/p>\n<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Monday,\u00a0December 9, at 6:00-8:00 pm<\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed\/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Abstract #4502<br \/>Poster\u00a0Presentation<br \/>Session<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Emmanuel Bachy<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Monday,\u00a0December 9, at 6:00-8:00 pm<\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #3080<br \/>Poster Presentation<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Gottfried von Keudel<\/p>\n<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Monday,\u00a0December 9, at 6:00-8:00 pm<\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma Treated with Odronextamab in the ELM-2 Study<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #4486<br \/>Poster Presentation<br \/>Session<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Sabarish Ayyappan<\/p>\n<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Monday,\u00a0December 9, at 6:00-8:00 pm<\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Long-Term Efficacy and Safety of Odronextamab in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from ELM-1 and ELM-2 Studies<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #3118<br \/>Poster\u00a0Presentation<br \/>Session<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">John N. Allan<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Sunday,\u00a0December 8, at 6:00-8:00 pm<\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Evaluation of CAR-HEMATOTOX Scoring as a Predictor of Infection Risk following Treatment with Odronextamab (a CD20\u00d7CD3 Bispecific Antibody) in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #3076<br \/>Poster\u00a0Presentation<br \/>Session<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Mathew Matasar<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Sunday,\u00a0December 8, at 6:00-8:00 pm<\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Evaluation of Baseline CAR-HEMATOTOX Scores to Predict Increased Severe Infection Risk in Patients with Relapsed\/Refractory Follicular Lymphoma Treated with Odronextamab<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #1650<br \/>Poster Presentation<br \/>Session<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Matthew Matasar<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Saturday,\u00a0December 7, at 5:30-7:30 pm<\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #1628<br \/>Poster Presentation<br \/>Session<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Stefano Luminari<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Saturday,\u00a0December 7, at 5:30-7:30 pm<\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed\/Refractory Mantle Cell Lymphoma following Prior BTK Inhibitor Therapy &#8211; A Cohort of the ELM-2 Study<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract Publication Only<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Srikanth Ambati<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">N\/A<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed\/Refractory Follicular Lymphoma (R\/R FL) after Two or More Lines of Systemic Therapy<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract Publication Only<\/p>\n<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Deepa Jagadeesh<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">N\/A<\/td>\n<\/tr>\n<tr>\n<td colspan=\"4\" style=\"border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><strong>Linvoseltamab<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; border-top: solid black 1pt ; vertical-align: top ; \">Linvoseltamab in Patients with Relapsed\/Refractory Multiple Myeloma: Longer Follow-Up and Selected High-Risk Subgroup Analyses of the LINKER-MM1 Study<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; border-top: solid black 1pt ; vertical-align: top ; \">Abstract #3369<br \/>Poster Presentation<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; border-top: solid black 1pt ; vertical-align: top ; \">Mansi R. Shah<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; border-top: solid black 1pt ; vertical-align: top ; \">Sunday,\u00a0December 8, at 6:00-8:00 pm<\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Soluble BCMA Dynamics in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in LINKER-MM1<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #3310<br \/>Poster Presentation<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Anasuya Hazra<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Sunday,\u00a0December 8, at 6:00-8:00 pm <\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Characterization of Linvoseltamab\u2019s BCMA Binding Epitope and Efficacy Against BCMA Mutations in Relapsed\/Refractory Multiple Myeloma<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #3265<br \/>Poster\u00a0Presentation<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Ken Lee &amp; Yi Zhou<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Sunday,\u00a0December 8, at 6:00-8:00 pm <\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">A CD38xCD28 Costimulatory Bispecific Antibody Demonstrates Potent Preclinical Combinatorial Activity with a BCMAxCD3 T Cell-Engager<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #3283<br \/>Poster\u00a0Presentation<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Kara Olson &amp; David J. DiLillo<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Sunday, December 8, at 6:00-8:00 pm <\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Reducing Time Toxicity for Anti-B-Cell Maturation Antigen (BCMA) Bispecific Treatment: Evidence from Pivotal Single-Arm Trial Data on Teclistamab, Elranatamab, and Linvoseltamab for Triple-Class Exposed (TCE) Relapsed\/Refractory Multiple Myeloma (RRMM)<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #2271<br \/>Poster Presentation Session<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Sikander Ailawadh<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Saturday, December 7, at 5:30-7:30 pm<\/p>\n<p>San Diego Convention, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Exposure-Response Analyses of Various Efficacy and Safety Endpoints in Support of Registrational Dose Selection of Linvoseltamab in Patients with Relapsed\/Refractory Multiple Myeloma<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract Publication Only<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Oleg Milberg<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">N\/A<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard-of-Care Therapies in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma Treated at IMWG Sites<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract Publication Only<\/p>\n<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Shaji Kumar<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">N\/A<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract Publication Only<\/p>\n<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Shaji Kumar<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">N\/A<\/td>\n<\/tr>\n<tr>\n<td colspan=\"4\" style=\"border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><strong>Additional Presentations<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; border-top: solid black 1pt ; vertical-align: top ; \">Efficacy and Safety of Pozelimab Plus Cemdisiran vs Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria who are Na\u00efve to Complement Inhibition*\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; border-top: solid black 1pt ; vertical-align: top ; \">Abstract #306<br \/>Oral Presentation Session<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; border-top: solid black 1pt ; vertical-align: top ; \">Christopher Patriquin<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; border-top: solid black 1pt ; vertical-align: top ; \">Saturday, December 7, at 4 \u2013 5:30 pm<\/p>\n<p>San Diego Convention Center, Room 11<\/td>\n<\/tr>\n<tr>\n<td style=\"border-left: solid black 1pt ; border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">TMPRSS6 Inhibition Rapidly Reverses Liver Iron Overload and Prevents an Increase of Splenic Pro-Inflammatory Macrophages in a Mouse Model of Beta-Thalassemia\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract #2473<br \/>Poster\u00a0Presentation Session<\/p>\n<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Heinrich E. Lob<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Sunday,\u00a0December 8, at 6:00-8:00 pm <\/p>\n<p>San Diego Convention Center, Halls G-H<\/td>\n<\/tr>\n<tr>\n<td style=\"border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">The Reality of Beta Thalassemia and Iron Chelation Therapy \u2013 A Qualitative Study Unveiling the Patient Burden<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Abstract Publication Only<\/p>\n<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">Chris Hartford<\/td>\n<td style=\"border-bottom: solid black 1pt ; border-right: solid black 1pt ; vertical-align: top ; \">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\u00a0*Agreement with Alnylam Pharmaceuticals, Inc.<\/p>\n<p>Linvoseltamab as well as the combination of pozelimab and cemdisiran are investigational, and the potential uses of odronextamab in R\/R MZL and rare subtypes of R\/R aggressive B-cell non-Hodgkin lymphoma are also investigational and have not been approved by any regulatory authority. Odronextamab is <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5L2l5OTnjecdDIKQLcEl4x_eQ1pu_gdYSCE601enQIrWqmMCb5q-TDTy3fqAjVH-_zVAgKHZEvcHWzzchflyaWGJ6RJRjpY_p-iF9Efh5YbgK196PIVxrK7nBsLSmt1pe2_Q7ziR3vWiCMAa4kOYE2JjnVzvPLdd1Av_rukdiU7HVSL1ggl9iOwFnE6ueNTpVHaDggwrRQd2tyLeU8oxrA==\" rel=\"nofollow\" target=\"_blank\" title=\"approved\">approved<\/a> in the European Union as Ordspono&#x2122; to treat R\/R FL or DLBCL after two or more lines of systemic therapy, but the safety and efficacy of odronextamab have not been fully evaluated by any other regulatory authority.<\/p>\n<p><strong>About Regeneron in Hematology<\/strong>\u00a0<br \/>At Regeneron, we\u2019re applying more than three decades of biology expertise with our proprietary\u00a0<em>VelociSuite<\/em><sup><em>\u00ae<\/em><\/sup>\u00a0technologies to develop medicines for patients with diverse blood cancers and rare blood disorders.<\/p>\n<p>Our blood cancer research is focused on bispecific antibodies that are being investigated both as monotherapies and in various combinations and emerging therapeutic modalities. Together, they provide us with unique combinatorial flexibility to develop customized and potentially synergistic cancer treatments.<\/p>\n<p>Our research and collaborations to develop potential treatments for rare blood disorders include explorations in antibody medicine, gene editing and gene-knockout technologies, and investigational RNA-approaches focused on depleting abnormal proteins or blocking disease-causing cellular signaling.\u00a0<\/p>\n<p><strong>About Regeneron&#8217;s\u00a0<\/strong><strong><em>VelocImmune<\/em><\/strong><sup>\u00ae<\/sup><strong>\u00a0Technology<\/strong>\u00a0\u00a0<br \/>Regeneron&#8217;s\u00a0<em>VelocImmune<\/em>\u00a0technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron&#8217;s Co-Founder, President and Chief Scientific Officer\u00a0George D. Yancopoulos\u00a0was a graduate student with his mentor\u00a0Frederick W. Alt\u00a0in 1985.They were the first to\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6T6kriN8F0KhxCwDmQAdzGTV9xCQKa26TPaq3apg9NlVyDqXMmmi9-azsa72j6RdzcGoUJhEX3sHl2rA_GNSG-bTNCP81cZYC1lyrEqa_QHITVj8QwmuLOi_h9zwTD2UNBZDPN8ZKB4vmmB6fgdKlc8g-UrfEJDqe4w3sJf94ElyWKsviMzrUImXXwGppQ-TOAK010rIzxAqPgwDMq9rSJJz62kSNT-PMNGGP9KFmhq0_TaIzDYogs8QAkawnsj23pmmVw2BpgGdgUWE_6MSFZYtS0CeH2wlTtE0HkvBuAl6Rz2GcWa-Y2TkTo9TWZmB7lVXcx-7Ek_xZhThbB6EgkXqBy9Jd7aW7TxSGlUJtLoJkPUQRswnjZe4Bel9Y6_hdWyM_oBRTwAJ4BruwBzFWPNGPqOkJDgZACFBDCUGX13s_gMOyCf4JAUwapRQrhfo\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>envision<\/u><\/a>\u00a0making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing <em>VelocImmune<\/em>\u00a0and related\u00a0<em>VelociSuite<\/em>\u00a0technologies.\u00a0Dr. Yancopoulos\u00a0and his team have used\u00a0<em>VelocImmune<\/em>\u00a0technology to create a substantial proportion of all original, FDA-approved or authorized fully human monoclonal antibodies. This includes REGEN-COV<sup>\u00ae<\/sup>\u00a0(casirivimab and imdevimab), Dupixent<sup>\u00ae<\/sup>\u00a0(dupilumab), Libtayo<sup>\u00ae<\/sup>, Praluent<sup>\u00ae<\/sup>\u00a0(alirocumab), Kevzara<sup>\u00ae<\/sup>\u00a0(sarilumab), Evkeeza<sup>\u00ae<\/sup>\u00a0(evinacumab-dgnb), Inmazeb<sup>\u00ae<\/sup>\u00a0(atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz<sup>\u00ae<\/sup> (pozelimab-bbfg).<\/p>\n<p><strong>About Regeneron<\/strong>\u202f\u00a0<br \/>Regeneron\u202f(NASDAQ: REGN) is a leading biotechnology company that invents,\u202fdevelops\u202fand commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to\u202frepeatedly and consistently translate science\u202finto medicine has led to numerous approved treatments and\u202fproduct candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious\u202fdiseases, and rare diseases.\u202f\u00a0<\/p>\n<p>Regeneron\u202fpushes the boundaries of scientific discovery and\u202faccelerates drug development\u202fusing\u202four proprietary technologies, such as\u202f<em>VelociSuite<\/em><sup>\u00ae<\/sup>, which produces optimized fully human antibodies and new classes of bispecific antibodies.\u202fWe are shaping the next frontier of medicine with data-powered insights from the\u202fRegeneron Genetics Center<sup>\u00ae<\/sup>\u202fand pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.\u00a0<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-QxxByIuUiMxdZls8eulLWDGODwX1L2bXZ19itG-QNX-qWTq2Z9hjIzr3kdiiho0u8akUMSIP2vsZ7SoCzqSl7nHVEYicItZT2aRu63_5jQ=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>www.Regeneron.com<\/u><\/a> or follow Regeneron on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pY0Y91IemYK_3qQK3kVBOSPfffJBGCiimGQUnriSGJKFj040pUuSANW0OlcGUdimmPydVbuIwrhUnKmW9UXeGdY4sqRqalqljBrW1JEmuu6xr5am1Az_iXJi-B6iAWPm2tjKRA9naF8p7hJZ_TvmgQ3nF34MnS44ZqVObgI4yvE=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>LinkedIn<\/u><\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GSvlb0R_iuUsE939dvLaI_Wd6OtQJob-5_5xsf0FJn8Y4sJHXNJ3vgs8S7ExI5lOSgG1rS1Z2GA127YvOJWQiIxRWS9KMcO2kj9GpDw8wA2MhE_bEBHthKzdmavUlm26KUB7P8xr_B-lPz8G189O-lnx5nnTTeaJTVpJUD4Y9lSmlr92kwGHI1g98KC22nUuuwZrDY8qZt3fhWq19Fagk_Y4oPwzdgwpmSEdnN-VDGiae8W11n8klCR1DlRje4VF\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>Instagram<\/u><\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ysLwHVMLswcwlmn5eE41w3EB0EfOD9C7la1aZxLHHeQH-X7aUmWKevxX512PotuJBLCFuerPbrSPbVYhKfn-mQqPRYYcxcSv5n3uStUu88oG5lhZmd01W9RuMPlYxKjL62HLQRjpb2Z3AzA_JgWnz_fEkpeEuCej0gGogHs_Xt5h1_RDtSMvot47m1IoTu3AeKdAhrfYYeGFtcjpNKbFRUqUJLkqeMaLAxm5jBkA9UHfWWYZuz3B6P3HXJtIz2O9\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>Facebook<\/u><\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=31RcXIOujk5nd8Ls-9CxVJLZv3Dlskq50ie88RuphW3JzznjNGkA_NU4FCTfzFvpB7sIhPDFpJisNno9WoMF3Vyw9iAchOWhm5w1xcOdCea7OPKZvDdP-cXn-WYWkib99XwbgGk79PdBQ1w1tiGLot63UXfukhgQEhWuBb0uoGjw1wZhTHj2jve3zP-XRO1xQaR54kWx9DgZZR2WfqzIHQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>X<\/u><\/a>.\u00a0\u00a0<\/p>\n<p><strong>Forward-Looking Statements and Use of Digital Media<\/strong>\u00a0<br \/><em>This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (\u201cRegeneron\u201d or the \u201cCompany\u201d), and actual events or results may differ materially from these forward-looking statements. Words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and\/or its collaborators or licensees (collectively, \u201cRegeneron\u2019s Products\u201d) and product candidates being developed by Regeneron and\/or its collaborators or licensees (collectively, \u201cRegeneron\u2019s Product Candidates\u201d) and research and clinical programs now underway or planned, including without limitation pozelimab in combination with cemdisiran, odronextamab, linvoseltamab, and the other programs discussed or referenced in this press release; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron\u2019s Product Candidates and new indications for Regeneron\u2019s Products, such as odronextamab for the treatment of follicular lymphoma in the United States, linvoseltamab for the treatment of<\/em> <em>relapsed\/refractory<\/em> <em>multiple myeloma in the United States and\/or European Union, and the other programs discussed or referenced in this press release; uncertainty of the utilization, market acceptance, and commercial success of Regeneron\u2019s Products and Regeneron\u2019s Product Candidates (such as those referenced above) and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron\u2019s Products and Regeneron\u2019s Product Candidates; the ability of Regeneron\u2019s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron\u2019s Products and Regeneron\u2019s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron\u2019s Products and Regeneron\u2019s Product Candidates (such as those referenced above) in patients, including serious complications or side effects in connection with the use of Regeneron\u2019s Products and Regeneron\u2019s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron\u2019s ability to continue to develop or commercialize Regeneron\u2019s Products and Regeneron\u2019s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron\u2019s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron\u2019s Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron\u2019s Products and Regeneron\u2019s Product Candidates (including biosimilar versions of Regeneron\u2019s Products); the extent to which the results from the research and development programs conducted by Regeneron and\/or its collaborators or licensees may be replicated in other studies and\/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron\u2019s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on Regeneron&#8217;s business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA<\/em><sup><em>\u00ae<\/em><\/sup><em> (aflibercept) Injection), other litigation and other proceedings and government investigations relating to the Company and\/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney&#8217;s Office for the District of Massachusetts), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron\u2019s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron\u2019s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2023 and its Form 10-Q for the quarterly period ended September 30, 2024. Any forward-looking statements are made based on management\u2019s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.<\/em><\/p>\n<p><em>Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron&#8217;s media and investor relations website (<\/em><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tCvGCl1f3bGba_06p47O38GP4UaWgbnQty8ywrz0XaAgEBoPZIDgCZKKvCsFIZUCBXcIFKpGU7q8MRYmKQndJDPcaEzR-S9WXK7_u7qqeQNMFxVXVtY0m_GmW5IRK5QD\" rel=\"nofollow\" target=\"_blank\" title=\"\"><em>https:\/\/investor.regeneron.com<\/em><\/a><em>) and its LinkedIn page (<\/em><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tCvGCl1f3bGba_06p47O31SEQplYDiJvZeZR7T7wBw4Gc-u-sDvOoeWC24mKRMMYnRado8J1hKGBwnjqx3AMsY5_CGpF2cWowy8GH8In7AfcDz-Tt0aR9oSiCkwjapse6NKBgE1MZjWP9zSnmkBulO5K_31l13uq5KbtLtzaGPEyzXWPF2g0AxbqB5Bh5AK9\" rel=\"nofollow\" target=\"_blank\" title=\"\"><em>https:\/\/www.linkedin.com\/company\/regeneron-pharmaceuticals<\/em><\/a><em>).<\/em><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"max-width:50%; width:50%; min-width:50%;;vertical-align: top ; \"><strong>Contacts:<\/strong><\/p>\n<p><strong>Media Relations<\/strong><br \/><strong>Tammy Allen<\/strong><br \/>Tel: +1 914-306-2698<br \/><u><a href=\"mailto:tammy.allen@regeneron.com\" rel=\"nofollow\" target=\"_blank\" title=\"tammy.allen@regeneron.com\">tammy.allen@regeneron.com<\/a><\/u><\/td>\n<td style=\"max-width:50%; width:50%; min-width:50%;;vertical-align: top ; \">\n<p><strong>Investor Relations<\/strong><br \/><strong>Mark <\/strong><strong>Hudson<\/strong><br \/>Tel: +1 914-847-3482<br \/><a href=\"mailto:mark.hudson@regeneron.com\" rel=\"nofollow\" target=\"_blank\" title=\"mark.hudson@regeneron.com\">mark.hudson@regeneron.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MmY2N2NlMzctN2M4Zi00MzhhLWE5YTEtZmI4OTI5NTY0MWI3LTEwMTc4MjM=\/tiny\/Regeneron-Pharmaceuticals-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first-line follicular lymphoma showcase compelling monotherapy potential and progress in the confirmatory trial Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma [&#8230;]\n","protected":false},"author":1,"featured_media":61641,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-61640","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH\" \/>\n<meta property=\"og:description\" content=\"Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemogl\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-13T12:06:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/11\/Regeneron-Pharmaceuticals-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH\",\"datePublished\":\"2024-11-13T12:06:14+00:00\",\"dateModified\":\"2024-11-13T12:06:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/\"},\"wordCount\":2793,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/\",\"name\":\"Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-11-13T12:06:14+00:00\",\"dateModified\":\"2024-11-13T12:06:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/","og_locale":"en_US","og_type":"article","og_title":"Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH","og_description":"Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemogl","og_url":"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-11-13T12:06:14+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/11\/Regeneron-Pharmaceuticals-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH","datePublished":"2024-11-13T12:06:14+00:00","dateModified":"2024-11-13T12:06:14+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/"},"wordCount":2793,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/","url":"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/","name":"Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-11-13T12:06:14+00:00","dateModified":"2024-11-13T12:06:14+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/61640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=61640"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/61640\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/61641"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=61640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=61640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=61640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}